Zyprexa/Zyprexa Zydis再普樂

Zyprexa/Zyprexa Zydis



Eli Lilly


Agencia Lei Va Hong
Concise Prescribing Info
Zyprexa tab/Zyprexa Zydis Treatment of schizophrenia & of moderate to severe manic episode. Prevention of recurrence in patients w/ bipolar disorder. Zyprexa inj Rapid control of agitation & disturbed behaviours in patients w/ schizophrenia or manic episode, when oral therapy is not appropriate.
Dosage/Direction for Use
Zyprexa tab/Zyprexa Zydis Adult Schizophrenia Initially 10 mg/day. Manic episode Monotherapy: Initially 15 mg as a single daily dose. Combination therapy: Initially 10 mg daily. Preventing recurrence in bipolar disorder Initially 10 mg/day. Daily dosage for schizophrenia, manic episode & recurrence prevention in bipolar disorder may be individually titrated w/in the range 5-20 mg/day. Elderly ≥65 yr & patients w/ renal &/or hepatic impairment Starting dose: 5 mg/day. Zyprexa inj Adult For IM use. Initially 10 mg as single IM inj. A 2nd inj of 5-10 mg may be administered 2 hr after the 1st inj depending on individual clinical status. Max: 20 mg/day (including oral form) & not exceeding 3 inj in 24-hr period. Elderly >60 yr Initially 2.5-5 mg. A 2nd inj of 2.5-5 mg may be administered 2 hr after the 1st inj depending on the patient's clinical status. Renal &/or hepatic impairment Initially 5 mg. Increase w/ caution.
May be taken with or without food: Orodispersible tab: Place in the mouth to rapidly disperse then swallow. May also disperse tab in a full glass of water or other suitable beverage (orange/apple juice/milk/coffee) immediately before administration.
Hypersensitivity. Patients w/ known risk of narrow-angle glaucoma.
Special Precautions
Not recommended in patients w/ dementia-related psychosis &/or behavioural disturbances; Parkinson's disease. Caution in patients w/ prostatic hypertrophy, paralytic ileus & related conditions; low leukocyte &/or neutrophil counts; history of seizures or patients subject to factors which may lower the seizure threshold. Neuroleptic malignant syndrome. Observe for signs & symptoms of hyperglycaemia. Monitor patients w/ DM or risk factors for DM for worsening of glucose control. Lipid alterations. Transient, asymptomatic elevations of hepatic aminotransferases. Discontinue if Drug Reactions w/ Eosinophilia & Systemic Symptoms (DRESS) is suspected. QTc prolongations. Venous thromboembolism. Combination w/ other centrally acting medicines & alcohol. Risk of tardive dyskinesia increases w/ long-term olanzapine exposure. Postural hypotension in elderly. Sudden cardiac death. May affect ability to drive or operate machinery. Pregnancy & lactation. Not indicated for childn & adolescents. Zyprexa tab Rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Zyprexa Zydis Phenylketonurics. Contains mannitol, Na methyl parahydroxybenzoate & Na propyl parahydroxybenzoate. Zyprexa inj Patients w/ agitation & disturbed behaviours related to conditions other than schizophrenia or manic episode; unstable medical conditions eg, acute MI, unstable angina pectoris, severe hypotension &/or bradycardia, sick sinus syndrome, or following heart surgery. Concomitant use of benzodiazepines & other medicinal products having haemodynamic properties similar to IM olanzapine. Observe patient for hypotension particularly for the 1st 4 hr following inj.
Adverse Reactions
Wt gain; somnolence; orthostatic hypotension; elevated plasma prolactin levels. Eosinophilia, leukopenia, neutropenia; elevated cholesterol, glucose & triglyceride levels, glucosuria, increased appetite; dizziness, akathisia, parkinsonism, dyskinesia; mild, transient anticholinergic effects including constipation & dry mouth; transient asymptomatic elevations of hepatic aminotransferases; rash; arthralgia; decreases libido in male & female, erectile dysfunction in male; asthenia, fatigue, oedema, pyrexia; increased alkaline phosphatase, high creatine phosphokinase, high γ-glutamyltransferase, high uric acid. Zyprexa inj Bradycardia w/ or w/o hypotension or syncope, tachycardia; postural hypotension, hypotension, inj site discomfort.
Drug Interactions
Induced metabolism w/ smoking & carbamazepine (CYP1A2 inducer). Inhibited metabolism w/ fluvoxamine (CYP1A2 inhibitor). Reduced bioavailability of oral olanzapine w/ activated charcoal. Antagonised effects of direct & indirect dopamine agonists. Exercise caution in patients who consume alcohol or receive medicinal products that can cause CNS depression. Not recommended w/ anti-Parkinsonian drugs in patients w/ Parkinson's disease & dementia. Use w/ caution when concomitantly administered w/ medicines known to increase QTc interval. Zyprexa inj Added somnolence w/ IM lorazepam. Potential for excessive sedation w/ parenteral benzodiazepine.
MIMS Class
ATC Classification
N05AH03 - olanzapine ; Belongs to the class of diazepines, oxazepines and thiazepines antipsychotics
Zyprexa coated tab 10 mg
Zyprexa coated tab 5 mg
Zyprexa powd for inj 10 mg
Zyprexa Zydis orodispersible tab 10 mg
Zyprexa Zydis orodispersible tab 5 mg
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in